Sun Pharmaceutical Industries has signed an agreement to acquire 100% of Mumbai-based Innovcare Lifesciences Pvt Ltd for ₹271 crore in cash, strengthening its product portfolio in the pharmaceuticals, nutraceuticals and cosmeceuticals segments.
The pharmaceutical company informed stock exchanges on Saturday that the acquisition will be completed on or before July 31, 2026. The transaction is not a related-party deal and Sun Pharma’s promoter group has no interest in the target company.
Strategic portfolio expansion
Sun Pharma said the acquisition is a strategic investment aimed at strengthening the company’s product portfolio. Innovcare Lifesciences is engaged in the marketing, distribution and sale of pharmaceutical drugs, nutraceutical products and cosmeceutical offerings in India.
The acquisition will be carried out through a cash consideration of around ₹271.2 crore, with Sun Pharma acquiring all outstanding shares of Innovcare.
Innovcare posts steady growth
Founded in July 2014, Innovcare has demonstrated consistent revenue growth over the past three financial years. The company reported revenue from operations of ₹94.06 crore in FY26, compared with ₹86.09 crore in FY25 and ₹80.93 crore in FY24.
The company operates exclusively in India and focuses on marketing and distribution across pharmaceutical, nutraceutical and cosmeceutical categories.
No regulatory approvals required
Sun Pharma said no governmental or regulatory approvals are required for the transaction. The acquisition is expected to enhance the company’s presence in specialised healthcare segments while broadening its product offerings.
The acquisition comes as Sun Pharma continues to pursue strategic investments to expand its portfolio and strengthen its position in the domestic healthcare market.